Additional file 1: Figure S1. of Prime and boost aerosol exposure via fog machine or shisha smoke followed by cinnamon hypersensitivity and anaphylaxis to spiced food

A) Chemical formulas of substances related to cinnamaldehyde which were related to adverse reactions in the patient; B) Chemical formulas of substances contained in smoke fluids; C) Glycerol can be transformed to acrolein under subtraction of water, and vice versa. (TIF 158 kb

TFF3 levels.

<p>Panel A: TFF3 serum levels, two data points outside the axis limits in CKD stages 2 and 5. Panel B: Urinary TFF3 concentrations, one data point outside the axis limits in CKD stage 2. Panel C: Fractional TFF3 excretion, one data point outside the axis limits in CKD stage 5. Each dot represents an individual patient. The line indicates the median. CKD, chronic kidney disease. Only significant p-values are given.</p

Correlation of TFF serum and urine levels with clinical and kidney function parameters.

<p>* indicates significance</p><p>Correlation of TFF serum and urine levels with clinical and kidney function parameters.</p

TFF1 levels.

<p>Panel A: TFF1 serum concentrations, three data points outside the axis limits in CKD stages 1, 2, and 3. Panel B: Urinary TFF1 levels, three data points outside the axis limits in CKD stage 3. Panel C: Fractional TFF1 excretion, six data points outside the axis limits in controls and CKD stages 1–4. Each dot represents an individual patient. The line indicates the median. CKD, chronic kidney disease. Only significant p-values are given.</p

Underlying kidney disease, baseline demographic data and laboratory variables.

<p>Data are given as median with range; CKD, chronic kidney disease. Patients specified with carcinoma were suffering from urothelial or renal cell carcinoma and underwent chemotherapy. No renal biopsy was obtained from patients with unknown entity, since proven diagnosis would not have changed treatment planning.</p><p>Underlying kidney disease, baseline demographic data and laboratory variables.</p

Calculated affinities energies and dissociation constants of ligands to Bos d 5.

<p>Calculated affinities energies and dissociation constants of ligands to Bos d 5.</p

Annexin V staining of PBMCs.

<p>PBMCs were left unstimulated or treated with iron-catechol alone or with PMA alone or in the presence of <i>apo</i>- or <i>holo</i>-Bos d 5. Living cells were gated on forward and side scatter and then plotted for CD4 and Annexin V. (A) Representative pictograms of PBMCs plotted for CD4 and Annexin V. (B) Summary of percentage of CD4+Annexin V+ cells. (C) Summary of percentage of CD4-Annexin V+ cells. Statistical analyses were conducted with repeated measures ANOVA following Newman-Keuls Multiple Comparison test. ***P<0.001, *P<0.05.</p

Bos d 5 is able to bind iron via siderophores.

<p>(A) Bos d 5 (1GX9) with Fe(DHBA)₂ (B) chemical structure of siderophores (C) UV-VIS spectra of Fe(DHBA) complex in the presence or absence of Bos d 5 or with Bos d 5 alone. (D) Iron-staining of <i>apo</i>- or <i>holo</i>-Bos d 5 as well as controls (buffer and iron-siderophore-complex) dotted on nitrocellulose-membrane.</p

Bos d 5 devoid of iron promotes IL13 and IFNγ secretion.

<p>(A) IL13 levels and (B<b>)</b> IFNγ levels of stimulated PBMCs. Statistical analyses were conducted with repeated measures ANOVA following Newman-Keuls Multiple Comparison test. **<i>P</i><0.01, *** P<0.001, ns not significant.</p

<i>Apo</i>-, but not <i>holo</i>-Bos d 5 promotes CD4 cells.

<p>PBMCs were treated with PMA alone or in the presence of <i>apo</i>- or <i>holo-</i>Bos d 5. (A) Living cells were gated on forward and side scatter, before gating on CD3 positive cells were performed. CD3 gated cells were then analyzed for their CD4 and CD8 expression.Representative pictograms of CD3 gated PBMCs plotted for CD4 and CD8 (B) Percentage of CD3+CD4+ cells. (C) Percentage of CD3+CD8+ cells. Statistical analyses were conducted with repeated measures ANOVA following Newman-Keuls Multiple Comparison test. **<i>P</i><0.01, ****<i>P</i><0.0001, ns not significant.</p